Seeking Alpha

Alkermes' OX2R Agonist For Narcolepsy Peaks Interest Amidst Strong Q3 Earnings

Alkermes exhibits strong Q3 earnings with increased revenues and product sales; Lybalvi shows promising growth. Alkermes' ALKS-2680 enters a competitive narcolepsy market with a novel mechanism, ...
Becker's ASC

Alpha-2 Agonists Reduce Opioid Use for Post-Surgical Patients, Study Says

Researchers at Geneva University Hospital in Geneva, Switzerland, found that the use of alpha-2 agonists with opioids in surgical patients decreased post-surgical opioid use by 25 to 30 percent. The ...
MarketWatch

Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET(R), at the ...

DF9001 is currently being evaluated for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma DF6215 is currently being evaluated for the ...
Business Wire

CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of ...

SAN MATEO, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has received a ...
Monthly Prescribing Reference

November 2024 Recap: Drug Pipeline Updates

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
WDAF-TV

Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at the Society ...

DF9001 is currently being evaluated for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma DF6215 is currently being evaluated for the ...